Full-Time

Hemophilia Thought Leader Liaison

Confirmed live in the last 24 hours

Deadline 10/16/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$144.8k - $209.1k/yr

Senior

Kansas City, MO, USA + 3 more

More locations: Phoenix, AZ, USA | Minneapolis, MN, USA | Denver, CO, USA

Remote

Candidates must reside within the geographic area of the assigned territory, or within a reasonable distance as determined by leadership.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree
  • KOL interaction experience
  • A minimum of five years of work experience in one or more of the following: Field sales, product marketing, or medical/clinical
  • Demonstrated leadership skills
  • Ability to present ideas effectively to individuals or groups targeting presentations to the needs of the audience
  • Strong organizational skills
  • Strong project management experience, including superior analytical and planning skills
  • Ability to manage multiple projects simultaneously
  • Ability to execute against strategic and tactical plans under tight timelines
  • Ability to travel to meetings/trainings/programs as necessary
  • Have valid driver’s license
  • Must reside within the geographic area of the assigned territory, or within a reasonable distance as determined by leadership
  • 60-80% travel likely; could be less based on geography
Responsibilities
  • Align with cross-functional colleagues to orchestrate resources with the top KOLs, as determined by the Brand Team through influence and centers of excellence mapping
  • Identify, profile, cultivate and maintain long-term relationships with KOLs within the Hemophilia community; influence podium presence
  • Engage in on-label conversations on topics such as product, disease state and company, at appropriate venues
  • Execute unique, on-label and approved KOL programming (e.g. disease state and product) as directed by leadership
  • Compliantly collaborate and communicate with the field team on each assigned KOL to ensure strategic and tactical cohesiveness
  • Serve as a single point-of-contact to resolve KOL issues
  • Execute a customer-centric needs-based approach with targeted KOLs
  • Plan and execute KOL engagements and executive encounters at local, regional and national conferences, field visits and other venues as directed in a compliant manner
  • Capture feedback derived from brand needs through live interactions with targeted customers and KOLs
  • Work with targeted KOLs to obtain feedback on new and existing brand-related strategies/materials (all materials and programs a TLL will request will be approved by legal, compliance and regulatory)
  • Participate as a member of a cross-functional brand team to provide feedback on strategy, messaging and tactical execution and novel programming, ideas, and concepts
  • Provide competitive intelligence gained through interactions to help shape strategy
  • Facilitate cross-functional planning, recruitment, and execution of regional and national advisory boards, capturing feedback to inform brand decisions
  • Identify, align, and recruit appropriate HCP/KOL consultants to meet the needs of marketing and achieve the goal for each project
  • Assist with on-label KOL development, including identification of and/or training/coaching of promotional speaker with approved slide decks and materials
  • Assist in the execution of speaker contracting when requested, including, but not limited to, completion of annual budget plan, recommendations, and nominations
  • Coordinate speaker training; ensure that speakers are competent and up to date on new information
  • Attend HCP Speaker programs to observe, coach and remediate the speaker when necessary to ensure compliant execution of content
  • Assist with new content creation and existing content updates and renewals
  • Manage monthly reporting on Speaker Program KPIs and field force performance
  • Serve as the single point of contact for high volume speaker logistics/scheduling and working cross-functionally to ensure appropriate communication
  • Lead planning, execution and pull-through of in-practice speaker programs
Desired Qualifications
  • Master’s degree in related field preferred
  • Experience in Hemophilia/Hematology HIGHLY desirable preferred
  • Launch experience preferred
  • Marketing experience preferred

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing extensive research and development to create new therapies and improve existing ones, ensuring they meet the needs of patients and healthcare providers. What sets Sanofi apart from its competitors is its strong commitment to R&D, strategic partnerships, and a diverse product portfolio that includes prescription medicines and vaccines. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The FDA approval of Dupixent addresses a large unmet need in dermatology.
  • Sanofi's 20% profit growth in Q1 2025 highlights effective market strategies.

What critics are saying

  • Increased competition in immunology could impact Sanofi's market share.
  • Potential delays in regulatory approvals may affect new product launches.
  • Integration challenges from acquisitions could disrupt operations and delay synergies.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company leverages strategic partnerships to enhance its innovative treatment pipeline.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...